Company intelligence / Profile preview

RoverX

New York City, New York, United Statesroverx.io ↗

Ownership: Private
Development stage: Other

Overview

Rover Diagnostics is developing a point-of-care RT-PCR testing device for OB/GYN clinics, aiming to deliver lab-quality results in under 20 minutes. The initial clinical focus is on common women’s health infections such as bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis. The company participated in the NIH RADx program to accelerate COVID testing solutions and plans broader applications for its technology beyond women’s health.

Therapeutic areas: Infectious DiseasesWomen's Health
Modalities: Device
Industry: Molecular Diagnostics

Partnerships

Columbia UniversityNIH RADx program

Beyond the preview

Go deeper on RoverX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RoverX.

Explore the full profile